Humatrope is a man-made form of human growth hormone. Humatrope (somatropin, rDNA origin) for injection is a form of human growth hormone used to treat growth failure in children and adults who lack natural growth hormone.
It was first approved in 1987 to treat children who are slowly growing because they do not make enough growth hormone on their own. Humatrope is available in 6 mg, 12 mg, and 24 mg cartridges for use in a HumatroPen injection device. It is also available in vials for use with a syringe and needle.
View Here @ Pediatric Growth Hormone Deficiency Market Share
Somatropin is a man-made version of the human growth hormone (GH), which is naturally produced by the pituitary gland and is necessary to stimulate growth in children. It is used to help children grow taller and help adults and children grow muscle. Somatropin is marketed under several brand names NutropinAQ (Ipsen/Genentech), Genotropin (Pfizer), etc.
However, Genotropin is slightly more popular than other recombinant human GH.
In March 2015, Ferring Pharmaceuticals received US FDA approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the US as Zomacton [somatropin (rDNA origin)] for injection, and its needle-free delivery system to be marketed in the US as ZOMA-Jet.
Ferring purchased the US rights to Zomacton, formerly Tevtropin, and to Zomajet, formerly Tjet, in December 2014 from Teva Pharmaceutical.
Omnitrope, a somatropin biosimilar, is a recombinant human growth hormone indicated for adult GHD. It is synthesized in a strain of Escherichia coli that has been modified by the addition of the gene for human growth hormone.
The drug is a sterile white lyophilized powder intended for subcutaneous injection.
The dynamics of the GHD market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.
Key players, such as Ascendis Pharma, Pfizer, Opko health, Lumos Pharma, and others are actively involved in developing new drugs for GHD.
Read More @ Pediatric Growth Hormone Deficiency Market Size